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At the end of the last century, in 1997, Jenicek [1] de-
fined evidence-based public health (EBPH) as the “…
conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of communi-
ties and populations in the domain of health protection, 
disease prevention, health maintenance and improve-
ment (health promotion)…”. Since then, other defini-
tions have also emerged [2, 3].
This concept is related to the concept of evidence-
based medicine (EBM). EBM has already had a great im-
pact on the practice of medicine, i.e., science-based clini-
cal practice, and produces clearly better clinical outcomes.
EBPH needs, in most cases, a multidisciplinary ap-
proach using information and knowledge from different 
scientific areas. This knowledge supports public health 
decision-making procedures that should always be based 
on the scientific evidence and available resources.
There is no doubt that the novel coronavirus disease 
(COVID-19) pandemic is a major public health crisis that 
has brought with it great challenges concerning global 
health; it has mobilized a lot of scientific areas aiming at 
improving risk assessment and, consequently, risk man-
agement. The collaboration between industry and several 
sciences, including medicine (clinical and public health 
practices) and other health sciences, made it possible, for 
example, to conduct risk assessment, introduce risk man-
agement, and develop diagnostic tests and vaccines in a 
very short period of time.
SARS-CoV-2 infection is highly contagious, mainly 
via the respiratory route like other known respiratory vi-
ruses. The virus has spread all over the world and from 31 
December 2019 until week 11 of 2021, a total of 123,636,852 
cases of COVID-19 have been reported (according to the 
applied case definitions and testing strategies in the af-
fected countries), associated with 2,721,891 deaths [4]. 
Currently, the reinfection rate seems more controlled in 
Europe, with asymmetries between countries, but further 
research will determine, unquestionably, improved evi-
dence-based decisions [5].
One of the most difficult challenges felt during this 
pandemic concerns the urgency of risk management. 
Risk management is being based on the scientific knowl-
edge that is emerging daily, with studies sometimes being 
contradictory. Public health resources are also scarce, as 
we were not prepared for such a calamity. As a result, 
there is not always a solid evidence base.
The global response to the COVID-19 pandemic has 
been exceptional, with unpreceded cooperation by differ-
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ent sectors of society. However, there is also great in-
equality regarding the scale and prompt delivery of health 
care. Therefore, a lot of work remains incomplete, and, so 
far, we do not have enough scientific knowledge for a ful-
ly EBPH approach to deal with the constant challenges of 
risk management.
Accordingly, countries and populations have rallied to 
fight the pandemic, often trying to provide an answer that 
appears to be a product of the balance between science 
and art. As a matter of fact, research and action have pro-
gressed almost to a point of “holding hands,” something 
never before observed.
Risk management and public health strategies are in-
fluenced by important social, economic, and politic con-
sequences. As highlighted by Brownson et al. [6] “… key 
components of EBPH include making decisions on the 
basis of the best available scientific evidence, using data 
and information systems systematically, applying pro-
gram-planning frameworks, engaging the community in 
decision-making, conducting sound evaluation, and dis-
seminating what is learned…”.
The exponential growth phases of the COVID-19 pan-
demic have been complex, and call for a continuous, mul-
tifaceted, and rapidly adjusting public health response 
which is not always evidence-based. Such a response 
should have more precise risk assessment, better expan-
sion of institutional partnerships, international coopera-
tion, and a huge investment in risk communication.
The COVID-19 pandemic changed our health care 
systems in a unique way due to prioritizing the manage-
ment of the pandemic and limiting the spread of the 
SARS-CoV-2 virus. This is in addition to the impact that 
the pandemic has had on our lifestyles [7], and preparing 
for new waves of the pandemic which has mobilized our 
current efforts.
One of the lessons to be learned all over the world from 
this pandemic is that, in the event of such a public health 
emergency, the weaknesses of our health care systems are 
exposed and are unprepared to cope with such a burden. 
Emergencies like the COVID-19 pandemic need global 
responses that are based on public health approaches (or 
preferably, on preventing disease and promoting health), 
which are, unfortunately, not the focus of most health 
care systems.
The Portuguese Journal of Public Health has engaged 
all its efforts to study and research COVID-19, with the 
aim of producing more scientific evidence for the devel-
opment of public health strategies to fight the spread of 
SARS-CoV-2 disease.
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